GENE ONLINE|News &
Opinion
Blog

2021-07-29| Asia-Pacific

Japan’s Chugai Infuses $500 Million for a New API Manufacturing Building

by Tyler Chen
Share To

With nearly $500 million (55.5 billion yen) investment, Japan’s Chugai Pharmaceutical adds another manufacturing building to produce active pharmaceutical ingredients (APIs) for small and mid-size molecule drugs. This is the third building Chugai established for this drug type.

 

FJ3 to Support Clinical Trials to Market Launch

The building, also known as FJ3, will be located in the Fujieda Plant along with FJ1 and FJ2 and is expected to go into full operation in March 2025.

“FJ3 will be a world-class production facility with advanced production technologies and automate manufacturing operations which enable labor-saving and productivity improvements, as well as thoroughly considering environment and safety,” said Osamu Okuda, President, and CEO of Chugai.

FJ3 will be a five-story isolated building and installed API production lines with advanced containment technologies to meet the manufacturing needs as more candidates are about to enter clinical trials. The facility will produce high potency API from early clinical trials to market launches.

The construction of FJ3 will begin in 2022 and finish in February 2024. Currently, FJ2 is still under construction and will be completed in 2022.

The mid-size molecule is Chugai’s third modality, following small molecules and antibodies. With the expectation of mid-size molecule drugs being the driving force for the firm’s medium to long-term growth, Chugai has established two buildings for production in 2019 and 2021.

Related Article: Chugai Initiates Actemra’s Phase 3 COVID-19 Trials in Japan

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
AstraZeneca Welcomes Neurofibromatosis And Asthma Treatment Approvals in Japan
2022-09-28
Daiichi Sankyo Wins Approval For Cancer Treatment in Japan
2022-09-26
Japan Approves AstraZeneca’s Complement Inhibitor For Rare Muscle Disorder
2022-08-26
LATEST
Repairing Genetic Mutations in Neurological Diseases with RNA Targeting Strategy
2022-11-25
AstraZeneca Thailand Wins Two ACES Awards 2022: “Industry Champions of the Year” and “Community Initiative”
2022-11-24
Mabwell Announces the U.S. FDA approval of 9MW3011 (FIC) for IND
2022-11-24
Novartis Shifts Gear To Phase 3 For Anti-Malaria Drug
2022-11-24
Moving Past Animal Models with Better Data for Drug Discovery
2022-11-23
IonOpticks ushers in a new age of proteomics with Aurora Frontier
2022-11-23
Korea Ginseng Corp.: As an adaptogenic herb, Korean red ginseng boosts the human immune response
2022-11-23
EVENT
2022-12-01
BIOCHINA 2022
Online
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!